| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cee6c6718e63bac2607267caf5105e54 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-573
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N5-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61N5-067
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-573 |
| filingDate |
2015-12-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2017-06-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b5def560e9383074d2862ddca7faebab
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5f37857a4b6d78c11f7c2af682ddaddb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dc09b75380757259e632d6a8d6bb4e24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5cbd6b08045eb6eba774476f66ad111e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ca590332f546b16000a3495f6e3d29ee |
| publicationDate |
2017-06-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
RU-2622031-C1 |
| titleOfInvention |
Method for combined treatment of macular oedema of retina |
| abstract |
FIELD: medicine. n SUBSTANCE: method for conbined treatment of macular oedema of retina includes intravitreous introduction of bevacizumab, carrying out retina laser coagulation, as well as additional subtenon injection of diprospan. Treatment is realised in three stages: first diprospan is introduced in dose 0.5 ml, then after 10-15 days laser coagulation of retina is performed and 15-20 days after laser coagulation bevacizumab in dose 0.05 ml is introduced. n EFFECT: reduction of frequency of intravotreous injections of neoangiogenesis inhibitors, stable increase of vision acuity, reduction of risk of development of side effects, associated with carrying out photodynamic therapy. n 2 ex |
| priorityDate |
2015-12-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |